Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage Anemia in Chronic Kidney Disease (Renal Anemia) - Overview Anemia in Chronic Kidney Disease (Renal Anemia) - Therapeutics Development Pipeline Overview Pipeline by Companies Products under Development by Companies Anemia in Chronic Kidney Disease (Renal Anemia) - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Anemia in Chronic Kidney Disease (Renal Anemia) - Companies Involved in Therapeutics Development 3SBio Inc Aevi Genomic Medicine Inc Akebia Therapeutics Inc Amgen Inc Bayer AG Betta Pharmaceuticals Co Ltd Biocad CCM Duopharma Biotech Bhd Chong Kun Dang Pharmaceutical Corp CJ HealthCare Corp Dong-A Socio Holdings Co Ltd FibroGen Inc GlaxoSmithKline Plc Intas Pharmaceuticals Ltd Japan Tobacco Inc JCR Pharmaceuticals Co Ltd Jiangsu Hansoh Pharmaceutical Group Co Ltd Myungmoon pharmaceutical Co Ltd Novartis AG Panacea Biotec Ltd Pfizer Inc PharmaEssentia Corp PhytoHealth Corp Pieris Pharmaceuticals Inc Reliance Life Sciences Pvt Ltd Xenetic Biosciences Inc Zydus Cadila Healthcare Ltd Anemia in Chronic Kidney Disease (Renal Anemia) - Drug Profiles BPI-5014B - Drug Profile Product Description Mechanism Of Action R&D Progress daprodustat - Drug Profile Product Description Mechanism Of Action R&D Progress darbepoetin alfa - Drug Profile Product Description Mechanism Of Action R&D Progress darbepoetin alfa - Drug Profile Product Description Mechanism Of Action R&D Progress darbepoetin alfa - Drug Profile Product Description Mechanism Of Action R&D Progress darbepoetin alfa - Drug Profile Product Description Mechanism Of Action R&D Progress darbepoetin alfa - Drug Profile Product Description Mechanism Of Action R&D Progress darbepoetin alfa - Drug Profile Product Description Mechanism Of Action R&D Progress darbepoetin alfa - Drug Profile Product Description Mechanism Of Action R&D Progress darbepoetin alfa - Drug Profile Product Description Mechanism Of Action R&D Progress EPO-018B - Drug Profile Product Description Mechanism Of Action R&D Progress epoetin alfa - Drug Profile Product Description Mechanism Of Action R&D Progress epoetin alfa - Drug Profile Product Description Mechanism Of Action R&D Progress epoetin zeta biosimilar - Drug Profile Product Description Mechanism Of Action R&D Progress ErepoXen - Drug Profile Product Description Mechanism Of Action R&D Progress erythropoietin - Drug Profile Product Description Mechanism Of Action R&D Progress FG-2216 - Drug Profile Product Description Mechanism Of Action R&D Progress HSA-EPO - Drug Profile Product Description Mechanism Of Action R&D Progress JTZ-951 - Drug Profile Product Description Mechanism Of Action R&D Progress MDGN-201 - Drug Profile Product Description Mechanism Of Action R&D Progress MMP-0101 - Drug Profile Product Description Mechanism Of Action R&D Progress molidustat - Drug Profile Product Description Mechanism Of Action R&D Progress PEG-EPO - Drug Profile Product Description Mechanism Of Action R&D Progress Peg-EPO - Drug Profile Product Description Mechanism Of Action R&D Progress PEG-EPO - Drug Profile Product Description Mechanism Of Action R&D Progress pegylated erythropoietin - Drug Profile Product Description Mechanism Of Action R&D Progress PHEP-01 - Drug Profile Product Description Mechanism Of Action R&D Progress PRS-080 - Drug Profile Product Description Mechanism Of Action R&D Progress Recombinant Protein for Renal Anemia - Drug Profile Product Description Mechanism Of Action R&D Progress roxadustat - Drug Profile Product Description Mechanism Of Action R&D Progress SSS-06 - Drug Profile Product Description Mechanism Of Action R&D Progress SSS-17 - Drug Profile Product Description Mechanism Of Action R&D Progress vadadustat - Drug Profile Product Description Mechanism Of Action R&D Progress Anemia in Chronic Kidney Disease (Renal Anemia) - Dormant Projects Anemia in Chronic Kidney Disease (Renal Anemia) - Discontinued Products Anemia in Chronic Kidney Disease (Renal Anemia) - Product Development Milestones Featured News & Press Releases May 25, 2017: FDA Advisory Committee Recommends Approval Of Pfizer's Proposed Biosimilar To Epogen/Procrit Across All Indications May 24, 2017: Akebia Initiates Phase 2 FO2RWARD Study of Vadadustat in Dialysis Patients with Anemia Related to Chronic Kidney Disease Hyporesponsive to Treatment with Erythropoiesis-Stimulating Agents Mar 30, 2017: Positive Results Published in Nephrology Dialysis Transplantation From Two China Phase 2 Trials of Roxadustat for Treatment of Anemia in Chronic Kidney Disease Mar 28, 2017: Akebia Announces Publication of Phase 2a Results for Vadadustat in Patients with Anemia Related to Chronic Kidney Disease Nov 24, 2016: GSK starts phase III programme with daprodustat for anemia associated with chronic kidney disease Oct 10, 2016: Xenetic Biosciences Reports Positive Topline Data from Third Cohort of Phase 2 Dose-Escalation Trial of ErepoXen for Anemia Sep 26, 2016: Akebia Announces Publication Highlighting Potential Benefits of HIF Treatments for Patients with Renal Anemia Sep 19, 2016: Akebia Announces Publication of Phase 2b Data for Vadadustat in Non-Dialysis Patients with Anemia Related to Chronic Kidney Disease Aug 22, 2016: Akebia Announces Publication Highlighting Need for New Solutions in Treating Dialysis Patients Aug 09, 2016: Kissei and JCR to Initiate a Phase III Clinical Trial of a Long-Acting Erythropoiesis-Stimulating Agent (Development Code: JR-131) Aug 08, 2016: Akebia Initiates INNO2VATE Phase 3 Program for Vadadustat in Dialysis Patients With Anemia Related to Chronic Kidney Disease Jul 25, 2016: Astellas And Fibrogen Announce First Patient Treated In Phase 3 Studies And Positive Phase 2 Results Of Roxadustat In Patients With Chronic Kidney Disease In Japan Jun 09, 2016: Fibrogen Announces Initiation By Astellas Of Phase 3 Clinical Study In Japan Of Roxadustat/ASP1517 For The Treatment Of Anemia Of Chronic Kidney Disease Triggering $10.0 Million Milestone Payment May 23, 2016: Akebia Announces Positive Vadadustat Data Demonstrating No Clinically Significant Drug-Drug Interaction May 05, 2016: Akebia Provides Update On Phase 3 INNO2VATE Program For Vadadustat Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer

List of Tables Number of Products under Development for Anemia in Chronic Kidney Disease (Renal Anemia), H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Products under Development by Companies, H1 2017 (Contd..2), H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by 3SBio Inc, H1 2017 Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Aevi Genomic Medicine Inc, H1 2017 Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Akebia Therapeutics Inc, H1 2017 Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Amgen Inc, H1 2017 Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Bayer AG, H1 2017 Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Betta Pharmaceuticals Co Ltd, H1 2017 Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Biocad, H1 2017 Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by CCM Duopharma Biotech Bhd, H1 2017 Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2017 Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by CJ HealthCare Corp, H1 2017 Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2017 Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by FibroGen Inc, H1 2017 Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by GlaxoSmithKline Plc, H1 2017 Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Intas Pharmaceuticals Ltd, H1 2017 Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Japan Tobacco Inc, H1 2017 Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by JCR Pharmaceuticals Co Ltd, H1 2017 Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Jiangsu Hansoh Pharmaceutical Group Co Ltd, H1 2017 Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Myungmoon pharmaceutical Co Ltd, H1 2017 Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Novartis AG, H1 2017 Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Panacea Biotec Ltd, H1 2017 Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Pfizer Inc, H1 2017 Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by PharmaEssentia Corp, H1 2017 Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by PhytoHealth Corp, H1 2017 Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Pieris Pharmaceuticals Inc, H1 2017 Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Reliance Life Sciences Pvt Ltd, H1 2017 Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Xenetic Biosciences Inc, H1 2017 Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Zydus Cadila Healthcare Ltd, H1 2017 Anemia in Chronic Kidney Disease (Renal Anemia) - Dormant Projects, H1 2017 Anemia in Chronic Kidney Disease (Renal Anemia) - Discontinued Products, H1 2017 List of Figures Number of Products under Development for Anemia in Chronic Kidney Disease (Renal Anemia), H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products by Targets, H1 2017 Number of Products by Stage and Targets, H1 2017 Number of Products by Mechanism of Actions, H1 2017 Number of Products by Stage and Mechanism of Actions, H1 2017 Number of Products by Routes of Administration, H1 2017 Number of Products by Stage and Routes of Administration, H1 2017 Number of Products by Molecule Types, H1 2017 Number of Products by Stage and Molecule Types, H1 2017

3SBio Inc Aevi Genomic Medicine Inc Akebia Therapeutics Inc Amgen Inc Bayer AG Betta Pharmaceuticals Co Ltd Biocad CCM Duopharma Biotech Bhd Chong Kun Dang Pharmaceutical Corp CJ HealthCare Corp Dong-A Socio Holdings Co Ltd FibroGen Inc GlaxoSmithKline Plc Intas Pharmaceuticals Ltd Japan Tobacco Inc JCR Pharmaceuticals Co Ltd Jiangsu Hansoh Pharmaceutical Group Co Ltd Myungmoon pharmaceutical Co Ltd Novartis AG Panacea Biotec Ltd Pfizer Inc PharmaEssentia Corp PhytoHealth Corp Pieris Pharmaceuticals Inc Reliance Life Sciences Pvt Ltd Xenetic Biosciences Inc Zydus Cadila Healthcare Ltd